Date：March 5, 2026
Agenda：
15:00-15:10 Welcome Opening&Introduction of the speakers and attendees and overview of the agenda
15:10-15:45 Designing a High-Impact Clinical Development Plan
15:45-16:00 Clinical Development Plan-Case Study 1: RSV Vaccines
16:00-16:20 Clinical Development Plan-Case Study 2: Zoster Vaccines
16:20-16:40 Panel Discussion & Summary of Panel discussion
16:40-16:45 Closing Remarks
Speakers introduction:
Laurence de Moerlooze, PhD
Laurence de Moerlooze, PhD, Chief Medical Officer at P95. She brings over 20 years of experience in vaccine development and pharmaceutical leadership, with direct responsibility for Phase 2 and Phase 3 vaccine programs across infectious diseases. Before joining P95, Laurence served as Executive Vice President and Chief Medical Officer at Bavarian Nordic (2020–2024), where she oversaw MVA-based vaccine programs, including late-phase clinical development and regulatory strategy. Earlier roles include Vice President and Global Program Lead at Takeda Vaccines, advancing Zika and Norovirus vaccine programs through Phases 1 and 2, and senior leadership positions at GSK Vaccines Global Headquarters in Belgium, where she led vaccine development and medical affairs for multiple adult and travel vaccine portfolios.
Adriana Bastidas, MD
Adriana Bastidas, MD, based in Belgium, Head of Medical and Scientific Strategy at P95. Adriana is an experienced vaccine and drug safety physician with a proven track record in various pharmaceutical companies for more than 17 years, including GlaxoSmithKline Vaccines , Mithra Pharmaceuticals, CureVac and Bavarian Nordic. At GSK, she worked as safety physician and medical, leading teams of medical monitors and medical data reviewers for vaccine development programs. During her time at GSK, she drove the successful implementation of phase 1 to 3 clinical trials and supported 2 successful new product license applications.
Special Guest introduction:
Dr. Haiwen Tang
Dr. Haiwen Tang graduated from Shanghai 2nd Medical University and previously served as a physician in the Department of Internal Medicine at Shanghai Ruijin Hospital. In 1993, after completing postdoctoral research in immunology at Paris Diderot University (University of Paris VII), France, he joined the University of Missouri in the United States to continue his research on the mechanisms of immune-mediated diseases.
From 1998 to 2023, he worked in Vaccines BU of GSK. He previously held positions as Medical Director for North Asia and Vice President of Medical Affairs for the Intercontinental Region.
During his tenure, he organized and participated in multiple vaccine clinical trials conducted in the Asian region, including clinical trials and epidemiological investigations for: the measles, mumps, and rubella (MMR) combined vaccine; acellular diphtheria, tetanus, and pertussis (DTaP) vaccine; hepatitis B vaccine; inactivated polio vaccine (IPV); hexavalent vaccine containing Haemophilus influenzae type b (Hib); cervical cancer vaccine; rotavirus vaccine; pandemic influenza vaccine; shingles (herpes zoster) vaccine; and RSV (respiratory syncytial virus) vaccine.
He has published over 40 papers in academic journals, including Vaccinology and The Journal of Immunology (USA).
Mr. Jinbo Gou
Mr. Jinbo Gou is Vice President of CanSino Biologics, Head of the Clinical Operations Center, as well as a Researcher.
He has nearly 20 years of experience in public health and vaccine research. Previously, he worked at China National CDC and Tianjin CDC, where he was engaged in infectious disease control and epidemiological research.
At CanSino Biologics, he established the Medical Department. Over the years, he has led his team in conducting domestic and international clinical studies for multiple innovative products, including meningitis, diphtheria-tetanus-pertussis (DTaP), pneumonia, COVID-19, polio, and tuberculosis. He has managed nearly 80 clinical studies, participated in multiple communications with domestic and international regulatory authorities as well as WHO to support product registration and marketing authorization.
He has undertaken multiple key provincial and ministerial-level R&D projects and published over 20 research papers in journals such as Lancet, Vaccine, Journal of Infection, and Emerging Microbes & Infections (EMI).
He also serves as a member of the Vaccine Clinical Research Branch of the Chinese Preventive Medicine Association; a member of the Clinical Research Branch and Enterovirus Disease Branch of CAV; Vice Chairman of the Vaccine Professional Committee of the Guangdong Respiratory and Health Association; and an expert reviewer for Tianjin Science and Technology Projects.
Additionally, he has received multiple honors, including recognition under the "131 Talent Program," Innovative Talent, Outstanding Scientific and Technological Talent, and the Tianjin May Day Labor Medal.
Moderator introduction:
Ms. Jacelyn Ji
Jacelyn Ji, holds a clinical medicine background and a Doctor of Business Administration (DBA) from Belhaven University in the United States.
Since entering the pharmaceutical R&D field in 2004, she has accumulated 21 years of experience in clinical research within pharmaceutical development.
Previously, Jacelyn served continuously for 15 years at Merck & Co., Inc. (MSD) China R&D Center, where she was in charge of global clinical study data management, clinical operations, and related functions, alongside team leadership responsibilities.
She later spent 5 years at a local Contract Research Organization (CRO) in China, leading initiatives in clinical research operations, building data management teams, and establishing operational frameworks. During this period, she guided her team to participate in both domestic and international clinical research projects focused on therapeutic and preventive vaccines.
Chairman introduction:
Ms. Yuan Yuan
Yuan Yuan, Secretary-General of CPIVC, has been working at PATH since January 2007, serving as Project Assistant, Project Administrator, Project Manager and Alliance Manager. She is currently the Country Representative in China, responsible for PATH's commercial and business development in China. During the 18 years of working in the vaccine field, she participated in WHO precertification of JE vaccine, rotavirus vaccine development, pneumonia conjugate vaccine development and training, OPV overseas clinical practice, Sabin IPV D antigen international standard development, HPV vaccine precertification and other projects. Familiar with vaccine life cycle production, quality, clinical, drug administration, pharmacovigilance, biosafety and other aspects. Prior to joining PATH, she was a project manager at Integrity Metals in Singapore and worked in Indonesia.
Original links: https://mp.weixin.qq.com/s/oYcn0kM_-iShPz9woNiyNA
京公网安备 11010802041931号 © 2024 cpivc.com